Evaluation of Lapatinib Powder-Entrapped Biodegradable Polymeric Microstructures Fabricated by X-Ray Lithography for a Targeted and Sustained Drug Delivery System

Materials

Eun-Goo Jeong¹  Hyung Jung Yoo²  Byeonghwa Song²  Hwang-Phill Kim¹  Sae-Won Han¹  Tae-You Kim¹  Dong-Il Dan Cho² 

[1] Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-799, Korea; E-Mails:;Inter-university Semiconductor Research Center, Automation System Research Institute, School of Electrical Engineering and Computer Science, Seoul National University, Seoul 151-744, Korea; E-Mails:

关键词: drug delivery system (DDS);    molecular targeted therapy;    lapatinib;    gastric cancer;    sustained drug release;    biodegradable polymer;    polycaprolactone (PCL);   

DOI  :  10.3390/ma8020519

来源: mdpi

【 摘 要 】

An oral medication of a molecular targeted drug, lapatinib, is taken regularly to maintain the drug concentration within the desired therapeutic levels. To alleviate the need for such cumbersome administration schedules in several drugs, advanced drug delivery systems (DDSs), which can provide time-controlled and sustained drug release, have recently received significant attention. A biodegradable synthetic polymer, such as polycaprolactone (PCL), is usually used as a carrier material for DDSs. In this paper, lapatinib powder-entrapped, PCL microstructures were fabricated with a precise X-ray lithography-based method. In vitro experiments on HER2 positive-human gastric cancer derived NCI-N87 cells were performed to appraise the drug release characteristics of the fabricated DDSs. The in vitro results indicate that after the X-ray lithography process, the lapatinib powder is still working well and show time- and dose- dependent drug release efficiencies. The cell growth inhibition characteristics of one hundred 40-μm sized microstructures were similar to those of a 1 μM lapatinib solution for over 144 h. In conclusion, the developed lapatinib-entrapped PCL microstructures can be used in molecular targeted delivery and sustained release as effective cancer-targeted DDSs.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.